This article is more than 5 years old. Information may no longer be current.

AMO first quarter net revenue grew 28% over last year

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA ANA, Calif. — Net revenue for Advanced Medical Optics was $192.5 million in the first quarter of 2005, a 28% from the same quarter in 2004, the company announced. The growth was attributed to the acquisition of Pfizer’s ophthalmic surgical business in mid-2004, a press release said.

Ophthalmic surgical revenue for the quarter grew 51.6% from the first quarter of 2004, to $118.7 million, the company stated. Total IOL sales rose 17.2% to $60.5 million, mostly due to the acquisition of the Pfizer Tecnis and Sensar lenses, the press release stated.

Viscoelastic sales rose dramatically, from $4.2 million in 2004 to $32.6 million during the first quarter of 2005. Again, the company noted the rise reflected the acquisition of Healon (sodium hyaluronate) from Pfizer, as well as growth in AMO Vitrax (sodium hyaluronate).

Sales of phacoemulsification products grew 5.2% during the quarter to $18.5 million, led by the company’s Sovereign system with WhiteStar technology.